Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
Neurology and Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 4, 2025
The
emergence
of
high-efficacy
disease-modifying
therapies
(HE
DMT)
for
multiple
sclerosis
(MS)
may
pose
challenges
to
the
administration
and
monitoring
burden
therapies.
This
article
presents
results
Delphi
consensus
method
generate
insights
from
experts
on
HE
DMT
in
Saudi
Arabia
with
a
special
focus
cladribine.
Between
January
March
2023,
two-round
modified
was
used
establish
regarding
DMTs
MS.
Through
questionnaire,
advisors
evaluated
17
properties
six
individual
basis
their
clinical
experience.
Advisors
were
required
rank
each
property
scale
1–5,
1
being
lowest
5
highest
burden.
Experts
ranked
cladribine
as
having
burden,
followed
by
ofatumumab
ocrelizumab.
Natalizumab
fingolimod
fourth,
alemtuzumab
had
During
first
round,
agreed
scores
properties,
except
hospital
visit
time
facility
use
during
ofatumumab,
route
fingolimod,
specific
side
effects
frequency
lab
tests
at
follow-up,
washout
period
natalizumab.
second
there
agreement
all
properties.
In
absence
alternative
scientific
data,
recommendations
provide
useful
into
MS
Arabia.
Язык: Английский
Real World Experience with Cladribine Tablets for Multiple Sclerosis at Four Academic Multiple Sclerosis Centers
Devon Conway,
Jacqueline A. Nicholas,
Nicolas R. Thompson
и другие.
Multiple Sclerosis and Related Disorders,
Год журнала:
2025,
Номер
94, С. 106272 - 106272
Опубликована: Янв. 14, 2025
Язык: Английский
Role of Immune Reconstitution Therapy with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in Older Patients
Neurology and Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 17, 2025
Язык: Английский
Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France
Neurology and Therapy,
Год журнала:
2024,
Номер
13(3), С. 503 - 518
Опубликована: Март 15, 2024
Cladribine
tablets
(CladT)
has
been
available
for
therapeutic
use
in
France
since
March
2021
the
management
of
highly
active
relapsing
multiple
sclerosis
(RMS).
This
high-efficacy
disease-modifying
therapy
(DMT)
acts
as
an
immune
reconstitution
therapy.
In
contrast
to
most
DMTs,
which
act
via
continuous
immunosuppression,
two
short
courses
oral
treatment
with
CladT
at
beginning
years
1
and
2
provide
long-term
control
MS
disease
activity
responders
treatment,
without
need
any
further
pharmacological
several
years.
Although
labelling
does
not
guidance
beyond
initial
courses,
real-world
data
on
from
registries
previous
clinical
trial
participants
patients
treated
routine
practice
indicate
that
is
controlled
a
period
this
time
substantial
proportion
patients.
Moreover,
experience
provided
useful
information
how
initiate
manage
CladT.
article
we,
group
expert
neurologists
France,
recommendations
initiation
DMT-naïve
patients,
switch
existing
DMTs
continuing
activity,
during
first
finally,
or
3,
4
after
initiating
We
believe
optimisation
its
will
maximise
benefits
especially
early
course
when
suppression
focal
inflammation
CNS
priority
limit
progression.
Язык: Английский